The The Company’s Product, hyaluronic acid three-injection linear intra-articular implant, Flexotron Plus (2%) has obtained medical device license.
· Issued by SciVision Biotech Inc.
Close
Today's Information
Provided by: SciVision Biotech Inc.
SEQ_NO
1
Date of announcement
2022/05/26
Time of announcement
18:24:12
Subject
The The Company's Product, hyaluronic acid
three-injection linear intra-articular implant, Flexotron
Plus (2%) has obtained medical device license.
Date of events
2022/05/26
To which item it meets
paragraph 51
Statement
1.Date of occurrence of the event:2022/05/26
2.Company name:SciVision Biotech Inc.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:Flexotron Plus (2%), a three-injection linear
intra-articular implant of hyaluronic acid developed and produced
by the company, has passed and obtained the medical device license
(P3H 2022/17103).
6.Countermeasures:make this announcement
7.Any other matters that need to be specified:This product contains
hyaluronic acid, which can increase joint lubrication and reduce joint
friction.For the majority of patients with degenerative knee arthritis,
it can inhibit the degeneration of cartilage, promote its metabolism,
relieve pain and discomfort, improve daily activities and increase range
of activities of joints. Russia has a population of 147 million, of
which about 13% have osteoarthritis. The company has obtained the Russian
national medical device license, for three-injection linear intra-articular
implant,which can increase the sales performance in the Russian market and
contribute to the company's revenue.
